MARKET

AGRX

AGRX

Agile Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.290
-0.100
-7.19%
After Hours: 1.320 +0.03 +2.33% 18:23 05/20 EDT
OPEN
1.390
PREV CLOSE
1.390
HIGH
1.420
LOW
1.250
VOLUME
334.78K
TURNOVER
0
52 WEEK HIGH
69.60
52 WEEK LOW
1.250
MARKET CAP
5.86M
P/E (TTM)
-0.0481
1D
5D
1M
3M
1Y
5Y
Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference
PRINCETON, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference taki...
GlobeNewswire · 5d ago
XERS, AGRX and LHDX among mid-day movers
Gainers: Data Storage Corporation (DTST) +40%. Indonesia Energy Corporation (INDO) +30%. Harpoon Therapeutics (HARP) +28%. Pulse Biosciences (PLSE) +24%. Praxis Precision Medicines (PRAX) +24%. Xeris Biopharma Holdings (XERS) +24%. Griffon
Seekingalpha · 6d ago
Recap: Agile Therapeutics Q1 Earnings
Agile Therapeutics (NASDAQ:AGRX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Benzinga · 05/12 21:35
Agile Therapeutics Q1 EPS $(3.78) Beats $(4.80) Estimate, Sales $1.76M Beat $1.22M Estimate
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(3.78) per share which beat the analyst consensus estimate of $(4.80) by 21.25 percent. This is a 52.75 percent increase over losses of $(8.00) per share
Benzinga · 05/12 21:34
Agile Therapeutics GAAP EPS of -$3.78 beats by $2.22, revenue of $1.76M beats by $0.54M
Agile Therapeutics press release (NASDAQ:AGRX): Q1 GAAP EPS of -$3.78 beats by $2.22. Revenue of $1.76M (+1366.7% Y/Y) beats by $0.54M. Shares +4.85%. “We produced another quarter of double-digit growth
Seekingalpha · 05/12 20:11
-- Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $1.76M, vs. Street Est of $1.22M
MT Newswires · 05/12 16:22
Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation
PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today publicly released the findings of its first year of post-marketing pharmacovigilance safety surveillance for Twirla® (levonorgest...
GlobeNewswire · 05/05 21:01
Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022
Live Conference Call and Webcast at 4:30 p.m. ETPRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2022 financial results after the market cl...
GlobeNewswire · 05/03 11:30
More
No Data
Learn about the latest financial forecast of AGRX. Analyze the recent business situations of Agile Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
50.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AGRX stock price target is 100.00 with a high estimate of 100.00 and a low estimate of 100.00.
High100.00
Average100.00
Low100.00
Current 1.290
EPS
Actual
Estimate
-6.91-5.18-3.46-1.73
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 76
Institutional Holdings: 30.75M
% Owned: 676.92%
Shares Outstanding: 4.54M
TypeInstitutionsShares
Increased
12
20.78M
New
5
119.39K
Decreased
10
23.60K
Sold Out
10
39.78K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Chairman/Chief Executive Officer/Director
Alfred Altomari
Chief Financial Officer/Senior Vice President
Dennis Reilly
Senior Vice President/General Counsel/Secretary
Geoffrey Gilmore
Senior Vice President
Robert Conway
Senior Vice President
Paul Korner
Lead Director/Independent Director
Seth Fischer
Independent Director
Sharon Barbari
Independent Director
Sandra Carson
Independent Director
John Hubbard
Independent Director
Ajit Shetty
Independent Director
Josephine Torrente
Independent Director
James Tursi
No Data
No Data
About AGRX
Agile Therapeutics, Inc. is a women’s healthcare company. The Company’s approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla uses its transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability, which may help support compliance. Its product pipeline consists of two types of product candidates: Twirla line extensions and other transdermal contraceptive product candidates. These potential product candidates are designed to address market needs of additional non-daily contraceptive options. Its Twirla line extensions include AG200-15 Extended Regimen (ER), AG200-15 SmP, AG200-15 ER SmP, and AG890, a P-only contraceptive patch.

Webull offers kinds of Agile Therapeutics Inc stock information, including NASDAQ:AGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGRX stock methods without spending real money on the virtual paper trading platform.